Beta-glucans for Hospitalised Patients With COVID-19

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomised trial aims to assess the role of beta1-3 glucan supplementation in improving clinical symptoms and other outcomes amongst hospitalised patients with COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Concentra Educacion e Investigación Biomédica
• Collaborator: Wohlstand Pharmaceutical

Criteria

Inclusion Criteria:

• Adult participants with an infection caused by SARS-CoV-2 confirmed with a reverse-transcription polymerase chain reaction (RT-PCR) obtained from a nasopharyngeal swab.

Exclusion Criteria:

• Life expectancy < 6 months

• Currently receiving invasive mechanical ventilation at baseline.

• Cognitive impairment that precludes the use of WURSS or understanding the informed consent form.

• Refusal to participate.